Teva Pharmaceuticals
Starting on the branded side, sales of Copaxone, the world's top multiple sclerosis treatment, rose 28%. The drug is clearly doing well, despite continued growth from Biogen Idec
On the generic side, Teva launched a generic version of Boehringer Ingelheim's Parkinson's disease drug Mirapex last quarter, which helped boost North American sales by 20%. Generic versions of Shire's Adderall XR, AstraZeneca's
Teva's generic-drug business will continue to grow, now that the company has outbid Pfizer
My biggest worry with Teva has been with its ability to continue its stellar growth record. There are a limited number of places left into which it can expand its generic-drug business, so it appears that long-term growth will have to come from branded drugs. Teva got one great home run in Copaxone, but it'll need to use some of its free cash to license others. It remains to be seen whether Teva can be as successful identifying potential branded-drug triumphs as it has been with making copycats of already-successful drugs.